Dainippon Sumitomo girds up to enter Japanese generic Aricept market
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP) is among the companies to have received regulatory approval in Japan for generic versions of Eisai's Alzheimer's disease therapy Aricept (donepezil), which are set to be included in the next reimbursement price listing of generics in the country in November.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.